By Counterforce Health Team in Raxone (idebenone) —

Getting Raxone (Idebenone) Covered by Blue Cross Blue Shield Michigan: Complete Coding, Prior Authorization, and Appeals Guide

Answer Box: Raxone (idebenone) is not FDA-approved and won't appear on Blue Cross Blue Shield of Michigan formularies, making coverage extremely challenging. Your best path: (1) Submit a formulary exception request through the BCBSM provider portal with comprehensive LHON documentation using ICD-10 code H47.22, (2) Include genetic testing results and detailed medical necessity letter, (3) If denied, file for Michigan DIFS external review within 127 days. Success requires thorough documentation and persistence through the appeals process.

Table of Contents

  1. Coding Basics: Medical vs. Pharmacy Benefit Paths
  2. ICD-10 Mapping for LHON
  3. Product Coding: HCPCS, J-Codes, and NDC
  4. Clean Request Anatomy
  5. Frequent Coding Pitfalls
  6. Verification with BCBS Michigan Resources
  7. Quick Pre-Submission Audit Checklist
  8. Appeals Playbook for Michigan
  9. Common Denial Reasons & Solutions
  10. FAQ

Coding Basics: Medical vs. Pharmacy Benefit Paths

Understanding how Blue Cross Blue Shield of Michigan processes Raxone (idebenone) claims starts with recognizing that this medication falls squarely under the pharmacy benefit, not medical benefit coverage.

Pharmacy Benefit Path:

  • Oral medications like Raxone's 150 mg tablets are processed through pharmacy benefits
  • Requires prior authorization through BCBSM's specialty drug pathway
  • Subject to formulary tier placement (Raxone is non-formulary)
  • Typically limited to 30-day supplies for specialty medications

Medical Benefit Path:

  • Reserved for injectable, infused, or clinic-administered drugs
  • Not applicable to Raxone since it's an oral tablet
  • Would require HCPCS J-codes (which Raxone doesn't have)
Note: Since Raxone lacks FDA approval, it has no standard U.S. NDC number or HCPCS J-code, making standard pharmacy billing impossible. Coverage requires a formulary exception process.

ICD-10 Mapping for LHON

Proper diagnosis coding is critical for any Raxone coverage request. The specific ICD-10 code for Leber's Hereditary Optic Neuropathy is H47.22.

Required Documentation Words That Support Coding

Your medical records must include specific language to support the H47.22 diagnosis:

  • "Leber's hereditary optic neuropathy" or "LHON" (not just "optic neuropathy")
  • "Genetically confirmed" with specific mutation notation (m.11778G>A, m.3460G>A, or m.14484T>C)
  • "Central or centrocecal scotoma"
  • "Bilateral vision loss" with specific visual acuity measurements
  • "Irreversible and permanent" nature of vision loss
  • "Legal blindness" status if visual acuity ≤20/200 in both eyes

Supporting ICD-10 Codes

While H47.22 is primary, these additional codes may strengthen your case:

  • Z87.891 - Personal history of nicotine dependence (relevant for LHON prognosis)
  • Z15.89 - Genetic susceptibility to other disease (for family history)

Product Coding: HCPCS, J-Codes, and NDC

Here's the challenging reality: Raxone has no standard U.S. coding because it's not FDA-approved.

Current Coding Status

Code Type Status Details
NDC Not assigned No FDA approval = no U.S. NDC
HCPCS J-Code None Not in 2025 CMS updates
Dosing Units 150 mg tablets Standard dose: 300 mg TID (6 tablets daily)
Billing Path Formulary exception Must request non-formulary coverage

Units Math for Requests

When requesting coverage, calculate units correctly:

  • Daily dose: 900 mg (300 mg three times daily)
  • Tablets per day: 6 tablets (150 mg each)
  • 30-day supply: 180 tablets
  • 90-day supply: 540 tablets (if approved for extended fills)

Clean Request Anatomy

A successful formulary exception request for Raxone must include these components:

Essential Documentation Checklist

Medical Necessity Letter Must Include:

  • Patient demographics and insurance information
  • Primary diagnosis: H47.22 - Leber's hereditary optic neuropathy
  • Genetic confirmation: Specific mtDNA mutation results
  • Visual function documentation: Current visual acuity, visual field results
  • Treatment rationale: Why Raxone is medically necessary
  • Dosing plan: 300 mg three times daily with meals
  • Monitoring plan: Regular ophthalmologic assessments

Supporting Documents:

  • Genetic testing results showing LHON mutations
  • Ophthalmology reports with visual acuity measurements
  • Visual field testing results
  • Family history documentation
  • Prior treatment attempts (if any)
Clinician Corner: Your medical necessity letter should reference the European Medicines Agency approval for LHON and cite relevant peer-reviewed studies on idebenone's mechanism of action in mitochondrial optic neuropathies. Include specific visual acuity measurements and emphasize the progressive nature of untreated LHON.

Frequent Coding Pitfalls

Avoid these common mistakes that lead to automatic denials:

Unit Conversion Errors

  • Wrong: Requesting by milligrams instead of tablet count
  • Right: Request 180 tablets for 30-day supply (6 tablets daily)

Mismatched Codes

  • Wrong: Using H47.9 (unspecified optic neuropathy)
  • Right: Use specific H47.22 for LHON

Missing Start Dates

  • Always include intended start date and duration of therapy
  • LHON treatment is typically long-term/indefinite

Documentation Gaps

  • Critical: Include genetic testing results
  • Essential: Document lack of FDA-approved alternatives
  • Required: Specify "orphan disease" or "rare disease" status

Verification with BCBS Michigan Resources

Before submitting any request, verify requirements through official BCBS Michigan channels:

Key Resources to Check

  1. BCBSM Provider Portal - Access prior authorization requirements
  2. Clinical Drug List/Formulary - Confirm non-formulary status
  3. Forms and Documents Page - Download current exception request forms
  4. Pharmacy Benefits Guidelines - Review specialty drug policies

Cross-Reference Steps

  1. Confirm current formulary status (Raxone will be non-formulary)
  2. Review specialty drug prior authorization requirements
  3. Check for any LHON-specific coverage policies
  4. Verify submission methods (portal vs. fax)

Quick Pre-Submission Audit Checklist

Use this checklist before submitting your Raxone coverage request:

Documentation Review

  • ICD-10 code H47.22 used consistently
  • Genetic testing results attached
  • Visual acuity measurements documented
  • Medical necessity clearly stated
  • Dosing specified as 300 mg TID
  • No FDA-approved alternatives noted

Submission Requirements

  • Correct BCBSM prior authorization form used
  • All required fields completed
  • Supporting documents attached
  • Prescriber signature and date included
  • Patient demographics match insurance card

Process Verification

  • Submitted through correct channel (provider portal)
  • Marked as "specialty drug exception" if applicable
  • Contact information provided for follow-up
  • Copy retained for records

Appeals Playbook for Michigan

When your initial request is denied (which is likely), Michigan offers robust appeal rights under the Patient's Right to Independent Review Act.

Internal Appeals Process

Timeline: BCBS Michigan has 60 calendar days to issue final internal appeal determination

Required Steps:

  1. Submit written appeal within 180 days of denial
  2. Include original denial letter
  3. Provide additional medical documentation
  4. Request peer-to-peer review if appropriate

External Review Through Michigan DIFS

Timeline: File within 127 days of final internal denial

Process:

  1. Submit request to Michigan Department of Insurance and Financial Services (DIFS)
  2. Standard review: Decision within 60 days maximum
  3. Expedited review: Decision within 72 hours (requires physician letter stating health risk)

Required Documentation:

  • Final denial letter from BCBS Michigan
  • All medical records supporting medical necessity
  • Physician letter explaining urgency (for expedited review)
  • Authorization for representative (if applicable)

Success Factors

Recent DIFS external review cases show that thorough clinical documentation significantly improves success rates. The Ozempic external review case (File No. 236281-001) demonstrates that well-documented rare disease cases can succeed even after initial denials.

Common Denial Reasons & Solutions

Denial Reason Solution Strategy
"Not FDA-approved" Cite orphan disease status, lack of alternatives, and EMA approval
"Experimental/investigational" Reference peer-reviewed studies and established European use
"Not medically necessary" Strengthen genetic confirmation and visual function documentation
"Step therapy required" Document no FDA-approved alternatives exist for LHON
"Non-formulary" Request formulary exception with comprehensive justification

FAQ

Q: How long does BCBS Michigan prior authorization take? A: Standard requests receive decisions within 72 hours of complete submission. Expedited requests are decided within 24 hours if medical urgency is documented.

Q: What if Raxone is non-formulary? A: You must request a formulary exception. This requires comprehensive medical necessity documentation and typically has lower approval rates than formulary medications.

Q: Can I request an expedited appeal? A: Yes, if waiting could seriously jeopardize your health or vision. Your physician must provide a letter documenting the medical urgency.

Q: Does step therapy apply to LHON treatment? A: Since no FDA-approved alternatives exist for LHON, traditional step therapy shouldn't apply, but you may need to document this explicitly.

Q: What happens if DIFS external review approves coverage? A: BCBS Michigan must provide coverage as directed. The external review decision is binding on the insurer.

Q: Are there any cost assistance programs for Raxone? A: Since Raxone isn't available in the U.S., traditional manufacturer assistance programs don't apply. Explore rare disease foundations and clinical trial opportunities.

Q: How do I know if my LHON diagnosis qualifies? A: You need genetic confirmation of LHON mutations (m.11778G>A, m.3460G>A, or m.14484T>C) plus documented visual impairment consistent with LHON.

Q: What if my doctor isn't familiar with Raxone coverage requests? A: Provide them with this guide and consider connecting with LHON specialist centers that have experience with international treatment protocols.

At Counterforce Health, we help patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters, plan policies, and clinical notes to identify the specific denial basis and draft point-by-point rebuttals aligned to each payer's rules. For complex cases like Raxone coverage requests, having the right documentation strategy can make the difference between approval and denial.

Whether you're navigating formulary exceptions, step therapy requirements, or external appeals, Counterforce Health provides the tools and expertise to strengthen your case with the right clinical evidence and procedural requirements that payers expect.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual circumstances, policy terms, and clinical documentation. Always consult with your healthcare provider and insurance company for specific guidance regarding your situation. Insurance policies and procedures may change; verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.